Idorsia Ltd is a Swiss biopharmaceutical company headquartered in Allschwil, Switzerland, specializing in the discovery, development, and commercialization of innovative small-molecule medicines. Founded in 2017 as a spinout from Actelion following Johnson & Johnson's $30 billion acquisition, Idorsia was established by renowned biotech entrepreneurs Jean-Paul Clozel and Martine Clozel with an initial team of approximately 650 employees.
| Product | Indication | Status | 2025 Revenue | Growth | Peak Sales Potential |
|---|---|---|---|---|---|
| QUVIVIQ (daridorexant) | Insomnia | Marketed (13+ countries) | CHF 134M | +120% YoY | Blockbuster trajectory (>CHF 1B) |
| TRYVIO/JERAYGO (aprocitentan) | Resistant Hypertension | Approved (US, EU, CAN) | Not disclosed separately | New product | $2.5B (analyst forecast) |
| Selatogrel | Acute Myocardial Infarction | Phase 3 (Viatris) | N/A (pipeline) | - | Blockbuster potential |
| Cenerimod | Systemic Lupus Erythematosus | Phase 3 (Viatris) | N/A (pipeline) | - | Significant (lupus nephritis) |
| Lucerastat | Fabry Disease | Registrational program | N/A (pipeline) | - | Orphan drug (~$200-350K/patient) |
| Name | Title | Background |
|---|---|---|
| Dr. Srishti Gupta | Chief Executive Officer | MD (Harvard), 18 years McKinsey Partner, joined as CEO July 2025 |
| Martine Clozel | Chief Scientific Officer | Co-founder, MD, PhD, endothelin research pioneer |
| Arno Groenewoud | Chief Financial Officer | Appointed June 2024 (succeeded André Muller) |
| Alberto Gimona | Head of Global Clinical Development | Clinical development expertise |
| Julien Gander | Group General Counsel | Joined June 2024 |
Per-Patient Revenue: $192,500/year net → $15,400-$23,100 commission (8-12%)
Addressable Population: 10,000-20,000 undiagnosed US patients (genetic prevalence 3x diagnosed cases)
Diagnostic Gap: Severe underdiagnosis; multi-year delays; symptoms misattributed
Ada Feasibility: Excellent - symptom clusters (neuropathic pain, GI, cardiac, renal, skin) + family history screening (5x multiplier effect)
Timeline: Approval ~2030-2031; begin partnership discussions 2028-2029
Action: Proactive pre-launch engagement with Idorsia to build diagnostic pathways, specialist networks, and Fabry-specific symptom checker.
| Rank | Drug | Fit Score | Per-Patient Revenue (Net) | Commission (8-12%) | Priority |
|---|---|---|---|---|---|
| 1 | Lucerastat (Fabry) | 9/10 | $192,500/year | $15,400-$23,100 | TOP PRIORITY (Pre-launch 2028-29) |
| 2 | Cenerimod (SLE/Lupus) | 8/10 | $18,000/year | $1,440-$2,160 | HIGH (Conditional on Phase 3 success end-2026) |
| 3 | QUVIVIQ (Insomnia) | 7/10 | $2,442/year | $195-$293 | IMMEDIATE (Volume play; approved product) |
| 4 | TRYVIO/JERAYGO (Resistant HTN) | 6/10 | $5,453/year | $436-$655 | MODERATE (Assess BP data integration) |
| 5 | Selatogrel (AMI) | 2/10 | Unknown | - | NOT SUITABLE (Acute emergency) |
| 6 | Clazosentan (aSAH) | 1/10 | - | - | NOT SUITABLE (ICU, Japan-only) |
| Timing | Catalyst | Impact |
|---|---|---|
| Q2 2026 | Daridorexant pediatric insomnia Phase 2 results | Label expansion potential; first DORA for pediatric population |
| Late 2026 | Selatogrel SOS-AMI Phase 3 first readout (Viatris) | Blockbuster potential for pre-hospital AMI treatment |
| End 2026 | Cenerimod Phase 3 registration study results (Viatris) | Lupus/lupus nephritis approval path; milestone/royalty driver |
| Q1 2027 | CCR6 antagonist (IDOR-1117-2520) Phase 2 PoC psoriasis | Pipeline validation; potential Th17 autoimmune platform |
| 2027 | Company profitability achievement (end-2027 target) | De-risks equity story; reduces financing/dilution risk |
| Q2 2028 | CXCR7 antagonist progressive MS PoC results | Pipeline expansion into CNS neurology |
| ~2029 | Lucerastat Fabry disease registrational filing (earliest) | Orphan drug approval path; high-value rare disease asset |
| Scenario | Price/Share (CHF) | Return | Key Assumptions |
|---|---|---|---|
| Bear Case | 0.50-1.50 | -50% to -75% | QUVIVIQ disappoints; TRYVIO partnership fails; Phase 3 failures; additional dilutive financing; bankruptcy/fire-sale risk |
| Base Case | 3.00-6.00 | -25% to +45% | QUVIVIQ CHF 300-400M by 2028; TRYVIO CHF 50-100M; selatogrel Phase 3 success; cenerimod mixed/positive; profitability 2027-2028 |
| Bull Case | 10.00-20.00 | +140% to +385% | QUVIVIQ blockbuster (CHF 500M+); TRYVIO $2.5B peak; selatogrel blockbuster AMI approval; cenerimod lupus approval; lucerastat Fabry approval; acquisition target |
Idorsia Ltd represents a high-risk, high-reward turnaround opportunity suitable for growth/recovery investors with tolerance for volatility and binary pipeline outcomes. The company has emerged from a near-death experience (2023-2024 crisis) to establish a credible path to profitability by 2027, driven by QUVIVIQ's commercial momentum and disciplined cost management.
At ~CHF 1.03 billion market capitalization (March 2026), Idorsia trades at elevated multiples (4.7x price/sales, 9.9x EV/sales) reflecting recovery from 2024 crisis lows and market pricing of pipeline option value. Current valuation implies base case scenario execution (QUVIVIQ reaching CHF 300-400M annual sales, TRYVIO contributing CHF 50-100M, selatogrel/cenerimod Phase 3 successes).